InSite Vision concludes patient recruitment in ISV-303 Phase 1/2 trial

InSite Vision‘s Phase 1/2 study is designed to evaluate the safety and efficacy of ISV-303 when administered either once or twice daily.

In the trial, the patients were randomized into one of four study arms examining ISV-303 as compared to the commercial bromfenac (once or twice daily) or vehicle (eg, DuraSite).

InSite Vision anticipates an additional Phase 2 clinical trial for ISV-303 to investigate, among other things, the pharmacokinetics of ISV-303 in humans.

InSite Vision CEO Timothy Ruane said that they believe the combination of their DuraSite technology with the approved NSAID bromfenac may create a superior new therapy to improve the outcome of patients undergoing ocular surgery.